#Aducanumab
Live, measured metrics for the hashtag #Aducanumab from the open social web. Every number carries a named source and the time it was fetched. Nothing is estimated.
Own #aducanumab
This #name is available to claim. It becomes your portal on the open agent web: this very page, a keyword you rank for by an open public stake, and a verifiable identity for AI agents. Nobody else sells a page like this for every #name.
Day-by-day usage
measured · mastodon.social (Mastodon public tags API) · fetched 2026-09-27 23:00 UTC0 uses by 0 unique accounts across the window. Real per-day counts, not estimates. Newest bar is today so far.
Related hashtags
measured · mastodon.social (Mastodon public search API) · fetched 2026-09-27 23:00 UTCNo related tags with measured usage found for #aducanumab.
Live pulse
measured · mastodon.social (Mastodon tag timeline) · fetched 2026-09-27 23:00 UTCEverything below is measured over the latest 16 public posts (spanning ~13445 hours).
Posting hours (UTC) — busiest: 03:00
Languages: English (12) · Finnish (2) · German (2)
Avg boosts / post: 2
Top of the latest posts
"I think one of the reasons Leqembi was approved (and Lilly's donanemab is likely to be, this year) is that aducanumab was approved. I remain skeptical that these drugs will provide any real-world benefit, but I am not skeptical at all of t
An expected news from Alzheimer therapies, https://www.alzforum.org/news/community-news/adieu-aduhelm-biogen-stops-marketing-antibody A bit nostalgic, though, because I was one of the few whose cognition improved (relatively, i.e. compared
@Lupposofi A couple of years ago, I coauthored a paper trying to measure the applicability of the #aducanumab (#Aduhelm)'s results applied to the real world practice of a #geriatric outpatient clinic (with special focus on older persons wit
What “aducanumab” means
WikipediaAducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. It is a monoclonal antibody that targets aggregated forms (plaque) of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai. Aducanumab is given via intravenous infusion.
“Aducanumab” on Wikipedia (CC BY-SA) →#aducanumab across platforms
every network with a public tag surfaceFollow #aducanumab straight to each platform’s own tag page. Where a platform publishes open data we measure it above; the rest lock their numbers behind paid APIs, so we link rather than guess.
Every number above is measured from a named public API at the shown fetch time. Nothing is estimated or extrapolated. Platforms that lock their data behind paid APIs are not shown. Agents: the same numbers, as JSON, at /api/hashtags/aducanumab